DealMatrix

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #21: Primer raises $100m Series C to scale AI payments platform

Primer, a digital payments orchestration platform, has raised $100 million in a Series C funding round to further advance its AI-powered operating layer designed for payments and finance teams.

The round was led by Sofina, with participation from Peak XV Partners.
Existing investors also took part, including Balderton Capital, Accel, ICONIQ Capital, Tencent, and Speedinvest.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

Primer operates at the intersection of financial technology, payments, and enterprise software, providing a payment orchestration platform that enables merchants to optimize and manage payment operations through a unified infrastructure layer.

Given the company’s current Series C stage, European benchmarks (Q1 2026) for FinTech and Payments businesses indicate valuation ranges of EV/Sales multiples of 5.42x-7.19x, and EV/EBITDA multiples of 18.66x-20.51x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform – Multiples Database at https://platform.dealmatrix.com

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #20: Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine

Isomorphic Labs, an AI-native drug discovery and development company, has announced a $2.1 billion Series B funding round aimed at accelerating the transition from breakthrough AI research to large-scale real-world drug development applications.

The round was led by Thrive Capital, with participation from existing investors Alphabet Inc. and GV (Google Ventures), alongside new backers including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund, further strengthening the company’s international investor base.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

Isomorphic Labs operates at the intersection of biotechnology, artificial intelligence, and pharmaceuticals, with a focus on accelerating drug discovery through advanced AI models and computational life sciences research. Given the company’s current Series B stage, European benchmarks (Q1 2026) for AI-enabled biotechnology and pharmaceutical businesses indicate ⤵️

Valuation ranges of EV/Sales multiples of 3.61x - 4.99x, and EV/EBITDA multiples of 16.84x - 20.68x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform – Multiples Database at https://platform.dealmatrix.com

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #19: CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine

CellCentric, a biotechnology company focused on developing a novel treatment for multiple myeloma, announced on Wednesday that it has secured $220 million in a Series D financing round to support its mid- and late-stage clinical trials. The round was led by Venrock.

The Cambridge, U.K.- and Boston-based biotech company previously raised an additional $120 million in a Series C funding round last year, co-led by RA Capital Management and Forbion.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

CellCentric operates at the intersection of biotechnology and pharmaceuticals, with a focus on developing innovative therapeutic solutions and advancing life sciences research. Given the company’s current stage, European benchmarks (Q1 2026) for biotechnology and pharmaceutical businesses indicate valuation ranges of EV/Sales multiples of 3.61x - 4.99x, and EV/EBITDA multiples of 17.86x - 20.68x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform – Multiples Database at https://platform.dealmatrix.com

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #16: Adcendo Raises $75M Series C for ADC Pipeline

Adcendo, a Copenhagen-based clinical-stage biotech company developing first-in-class antibody-drug conjugates (ADCs) for high unmet-need cancers, has raised $75 million in an oversubscribed Series C round led by JEITO Capital.

The round brings in new investors including Vida Ventures, LLC, Bpifrance, and EIFO, alongside continued backing from existing investors such as RA Capital Management and TCGX.

👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮!

ADCendo operates in the biotechnology and pharmaceutical sector, developing targeted therapies at the intersection of advanced science and precision medicine. In line with its Series C stage, European benchmarks (Q4 2025) for Biotech and Pharmaceuticals indicate valuation ranges of EV/Sales 3.71x - 4.74x and EV/EBITDA 19.32x - 21.52x.

➡️ Further information on valuation multiples in these sectors is available through the DealMatrix Platform: https://platform.dealmatrix.com